A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Not yet recruiting
- Conditions
- Biliary Tract Cancer
- Registration Number
- NCT06793709
- Lead Sponsor
- Eisai Co., Ltd.
- Brief Summary
The primary purpose of this study is to investigate the safety of Tasfygo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.
Exclusion Criteria
Not applicable.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Participants With Adverse Drug Reactions Up to 1 year
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Best Overall Response (BOR) Based on Physician's Assessment Up to 1 year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does Tasfygo target FGFR2 fusion-positive biliary tract cancer mechanisms post-chemotherapy?
What is Tasfygo's safety profile compared to standard-of-care therapies for FGFR2+ biliary cancer?
Which biomarkers beyond FGFR2 fusion predict response to Tasfygo in biliary tract cancer?
What adverse events are associated with Tasfygo in FGFR2+ biliary cancer patients post-chemo?
How does Tasfygo compare to other FGFR inhibitors like infigratinib in biliary cancer treatment?